Wolverine Trading
VIRX

Wolverine Trading’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Wolverine Trading’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-386
Closed -$4K – 5299
2020
Q2 		$4K Sell
386
-171
-31% -$2.58K ﹤0.01% 4472
2020
Q1 		$8K Buy
557
+183
+49% +$3.97K ﹤0.01% 4496
2019
Q4 		$4K Sell
374
-209
-36% -$3.5K ﹤0.01% 4573
2019
Q3 		$15K Sell
583
-66
-10% -$1.91K ﹤0.01% 4169
2019
Q2 		$16K Buy
649
+238
+58% +$9.2K ﹤0.01% 4297
2019
Q1 		$17K Buy
+411
New +$9.31K ﹤0.01% 4413
2018
Q4 		– Sell
-1,371
Closed -$96K – 5520
2018
Q3 		$96K Buy
1,371
+765
+126% +$58.1K ﹤0.01% 4556
2018
Q2 		$58K Hold
606
– – ﹤0.01% 4870
2018
Q1 		$58K Sell
606
-425
-41% -$72.9K ﹤0.01% 4870
2017
Q4 		$133K Buy
1,031
+540
+110% +$50.6K ﹤0.01% 4355
2017
Q3 		$33K Buy
491
+154
+46% +$12.6K ﹤0.01% 4281
2017
Q2 		$32K Sell
337
-54
-14% -$6.2K ﹤0.01% 4117
2017
Q1 		$56K Buy
+391
New +$55.9K ﹤0.01% 3983
2016
Q4 		– Sell
-394
Closed -$60K – 5311
2016
Q3 		$60K Buy
+394
New +$55.6K ﹤0.01% 4364

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's VIRX Position: Q3 2020 in Review

Wolverine Trading sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2020, closing a stake of 340 shares — an estimated $2.97K sold.

Wolverine Trading first reported a position in VIRX in Q2 2016 and held it in 8 quarters. The position peaked at $59K in Q1 2017. 28 funds tracked by Wall St. Rank hold VIRX as of Q3 2020.

  • Wolverine Trading reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Wolverine Trading sold 340 Viracta Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $2.97K.
  • Wolverine Trading first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2016 and held it in 8 quarters.
  • Wolverine Trading's Viracta Therapeutics, Inc. Common Stock position peaked at $59K in Q1 2017.
  • 28 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Wolverine Trading's 13F filing for Q3 2020, filed 13 Nov 2020.